• Blog
  • Hemophilia A and B Therapeutics Materials Market Analysis | 2021-2026

    Hemophilia A and B Therapeutics Materials Market Analysis | 2021-2026

    Hemophilia A and B Therapeutics Materials Market Analysis | 2021-2026
    Report code - SR1517 Delivery - 2 Weeks
    Hemophilia A and B Therapeutics Materials Market Growth, Trends, Dynamics & Market Ins See more...

    Market Insights

    The growth of the Hemophilia A and B therapeutics materials market is primarily driven by increasing incidences of blood disorders. Rising initiatives aimed at creating awareness among consumers regarding the prevalence of blood-related diseases are likely to drive the market growth further. In addition to this, increasing investment in research and development activities to develop novel drugs is likely to create lucrative opportunities for the players operating in the global Hemophilia A and B therapeutics materials market in the coming years.

    What is hemophilia?

    Hemophilia can be defined as a medical condition in which the ability of the blood to clot is severely reduced which causes the sufferer to bleed severely. Hemophilia is mainly caused by a hereditary lack of a coagulation factor, most often factor VIII. The drugs used to treat Hemophilia A and B include desmopressin, octocogalfa, nonacogalfa and others.

    COVID-19 Impact

    The COVID-19 outbreak posed significant challenges across verticals worldwide. It impacted the growth of the Hemophilia A and B therapeutics materials market negatively as the therapeutic procedures/treatment for diseases other than covid-19 declined due to fear of coronavirus infection. Also, supply chain disruptions due to the imposition of the lockdown affected the product availability on time and thus, affected the market growth.

    Key Players

    Key players operating in the Hemophilia A and B Therapeutics Materials market are-

    • Eagle Biologics, Inc. (US)
    • Spark Therapeutics, Inc. (US)
    • Alnylam Pharmaceuticals Inc. (US)
    • Sangamo Therapeutics, Inc. (US)
    • Novo Nordisk A/S (Denmark)
    • Shire plc (US)
    • The Chugai Pharmaceutical Co., Ltd. (Japan)
    • Bayer AG (Germany)
    • CSL Behring (US)
    • Pfizer Inc. (US).

    Segments' Analysis

    End-Use Trends

    The Hemophilia A and B therapeutics materials market has been bifurcated into dental clinics, hospitals, and ambulatory surgical centers. The hospital's segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment can be attributed to the presence of established healthcare infrastructure and professional staff.

    Regional Analysis

    By region, the North American market accounted for the largest market share in 2020 and is projected to grow at a robust CAGR during the review period. This can be attributed to the high demand for advanced drugs to treat Hemophilia coupled with the presence of key market players such as Eagle Biologics, Inc. (US) and Spark Therapeutics, Inc. (US). The market growth in Asia-Pacific is expected to be driven by rising consumer awareness related to blood disorders.

    To get the full scope of the report, Register Here

    Target Audience

    Here is the list of the group of customers that the market hopes to have the greatest opportunity to convert-

    • Distributors
    • Suppliers
    • Manufacturers
    • Logistics organizations
    • Government bodies

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

    What deliverables will you get in this report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth analysis of the Hemophilia A and B Therapeutics Materials Market

    How lucrative is the future?

    Market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional and country level historical data and forecasts

    Which are the most attractive market segments?

    Market segment analysis and forecast

    Which are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirement?

    10% free customization

    Research Methodology

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

    Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

    Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    Eagle Biologics, Inc. (US), Spark Therapeutics, Inc. (US), Alnylam Pharmaceuticals Inc. (US), San-gamo Therapeutics, Inc. (US), Novo Nordisk A/S (Denmark), Shire plc (US), The Chugai Pharma-ceutical Co., Ltd. (Japan), Bayer AG (Germany), CSL Behring (US) and Pfizer Inc. (US) are among the key players in the hemophilia A and B therapeutics materials market.

    Increasing incidences of blood disorders is the prime factor driving the growth of hemophilia A and B therapeutics materials market.

    The hospital's segment is expected to register significant growth in the hemophilia A and B therapeutics materials market in the coming years.

    North America accounted for the largest share in the hemophilia A and B therapeutics materials market in 2020.